Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Inhibition of the cyclooxygenase isoenzymes COX-1 and COX-2 provide neuroprotection in the MPTP-mouse model of Parkinson's disease
Autore:
Teismann, P; Ferger, B;
Indirizzi:
Swiss Fed Inst Technol, Behav Neurobiol Lab, CH-8603 Schwerzenbach, Switzerland Swiss Fed Inst Technol Schwerzenbach Switzerland CH-8603 ch, Switzerland Univ Marburg, Fac Pharm, Inst Pharmacol & Toxicol, Marburg, Germany Univ Marburg Marburg Germany Inst Pharmacol & Toxicol, Marburg, Germany
Titolo Testata:
SYNAPSE
fascicolo: 2, volume: 39, anno: 2001,
pagine: 167 - 174
SICI:
0887-4476(200102)39:2<167:IOTCIC>2.0.ZU;2-#
Fonte:
ISI
Lingua:
ENG
Soggetto:
NF-KAPPA-B; NITRIC-OXIDE SYNTHASE; SUBSTANTIA-NIGRA; FACTOR-ALPHA; GROWTH-FACTOR; C-JUN; MICE; BRAIN; SALICYLATE; ACTIVATION;
Keywords:
acetylsalicylic acid; meloxicam; inflammation; neurodegeneration; substantia nigra;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Life Sciences
Citazioni:
49
Recensione:
Indirizzi per estratti:
Indirizzo: Ferger, B Swiss Fed Inst Technol, Behav Neurobiol Lab, Schorenstr 16, CH-8603 Schwerzenbach, Switzerland Swiss Fed Inst Technol Schorenstr 16 Schwerzenbach Switzerland CH-8603
Citazione:
P. Teismann e B. Ferger, "Inhibition of the cyclooxygenase isoenzymes COX-1 and COX-2 provide neuroprotection in the MPTP-mouse model of Parkinson's disease", SYNAPSE, 39(2), 2001, pp. 167-174

Abstract

To study the possible role of the isoenzymes of cyclooxygenase COX-1 and COX-2 in the MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine) mouse modelof Parkinson's disease we used acetylsalicylic acid, a COX-1/COX-2 inhibitor, in comparison with meloxicam, a preferential COX-2 inhibitor. As markers of protection we determined the effects on MPTP-induced striatal dopaminedepletion, locomotor activity, cell loss, and tyrosine hydroxylase immunoreactivity (TH-IR) in the substantia nigra pars compacta. Male C57BL/6 mice (n = 82) were treated with a single dose of acetylsalicylic acid (10, 50, 100 mg/kg i.p.) or meloxicam (2, 7.5, 50 mg/kg i.p.) immediately prior to administration of MPTP (30 mg/kg s.c.) or saline. After 7 days the mice were sacrificed to analyze striatal dopamine and metabolite levels. Nigral sections were processed for Nissl-staining and TH-IR. In the saline-treated MPTPcontrol group striatal dopamine levels were reduced to 15.9% of control values. Dopamine depletion was significantly attenuated to values of 37.1 and38.6% of saline control values by acetylsalicylic acid (50 and 100 mg/kg) and to values of 36 and 40% by meloxicam (7.5 and 50 mg/kg), respectively. MPTP-induced decrease of locomotor activity was significantly attenuated byacetylsalicylic acid and meloxicam. Remarkably, the MPTP-induced decrease of TH-IR as well as the loss of nigral neurons was nearly completely prevented by acetylsalicylic acid (100 mg/kg) and meloxicam (7.5 and 50 mg/kg). In conclusion, the inhibition of either COX-1/COX-2 by acetylsalicylic acid or preferentially COX-2 by meloxicam provided a clear neuroprotection against MPTP-toxicity on the striatal and nigral levels. (C) 2001 Wiley-Liss, Inc.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 26/01/20 alle ore 01:02:13